Timothy Pardee

Professor

Atrium Health Wake Forest Baptist

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Timothy Pardee is a faculty member at Atrium Health Wake Forest Baptist in the United States. His research primarily focuses on acute myeloid leukemia, exploring various therapeutic interventions and outcomes in both older adults and patients undergoing intensive treatment. Recent publications include studies on the efficacy of novel therapies, patient assessments, and the impacts of post-remission treatments in AML.

Articles (10)

Year:

2025

Year:

2025

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

Wake Forest School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Timothy Pardee

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia.

Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia

HDirect-MAP: Projection-free single-cell modeling of response to checkpoint immunotherapy

Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML)

Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study.

A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Efficacy of 10-day decitabine in acute myeloid leukemia.

Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.

Collaborators (5)

Lance Miller

Wendy Demark-Wahnefried

Guangxu Jin

Bernard Tawfik

Janet Tooze

Make your next move.